Conditions · Pancreatic cancer
Pancreatic cancer — frontier options in Utah
Prefer to look first? Browse the live map without signing up.
30 open options
- TRIALPHASE1 / PHASE2RECRUITING
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VMD-928 100 mg Tablet · VMD-928 Tablet and Pembrolizumab (200 mg) — 15 sites
- TRIALPHASE1RECRUITING
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
KST-6051 — 9 sites
- TRIALNARECRUITING
Increasing Germline Genetic Testing for Patients With Cancer
Implementation strategies — 10 sites
- TRIALPHASE1RECRUITING
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Sofe-M · bevacizumab · carboplatin — 24 sites
- TRIALPHASE1RECRUITING
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
LY4052031 — 39 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
BMS-986523 · Gemcitabine · Nab-Paclitaxel — 8 sites
- TRIALPHASE3RECRUITING
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Paltusotine · Placebo — 73 sites
- TRIALPHASE1RECRUITING
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
PT0511 · Cetuximab — 9 sites
- TRIALPHASE2 / PHASE3RECRUITING
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Zanzalintinib · Everolimus — 126 sites
- TRIALPHASE1RECRUITING
A Study of MGC026 in Participants With Advanced Solid Tumors
MGC026 Dose Escalation · MGC026 Dose for Expansion — 12 sites
- TRIALPHASE1RECRUITING
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
LY3962673 · Cetuximab · Gemcitabine — 52 sites
- TRIALPHASE1RECRUITING
A Study of MGC028 in Participants With Advanced Solid Tumors
MGC028 — 7 sites
- TRIALPHASE3RECRUITING
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RYZ101 · Everolimus · Sunitinib — 54 sites
- TRIALPHASE2RECRUITING
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Biospecimen Collection · Computed Tomography · Magnetic Resonance Imaging — 454 sites
- TRIALPHASE1 / PHASE2RECRUITING
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
ADC — 7 sites
- TRIALPHASE1 / PHASE2RECRUITING
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
TNG462 · RMC-9805 · RMC-6236 — 18 sites
- TRIALPHASE1RECRUITING
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
BBO-11818 · Pembrolizumab · Platinum chemotherapy (cisplatin or carboplatin) — 17 sites
- TRIALPHASE1RECRUITING
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDE892 · IDE397 — 23 sites
- TRIALPHASE3RECRUITING
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
INCB161734 · Placebo · Investigator's choice of chemotherapy — 228 sites
- TRIALPHASE1 / PHASE2RECRUITING
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
RMC-6236 — 21 sites
- TRIALPHASE3RECRUITING
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
daraxonrasib — 78 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
VS-7375 · Cetuximab · Carboplatin + Pemetrexed + Pembrolizumab — 14 sites
- TRIALPHASE2RECRUITING
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
VS-7375 · cetuximab — 29 sites
- TRIALPHASE1 / PHASE2RECRUITING
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
JAB-23E73 · JAB-23E73 · JAB-23E73 — 4 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
ART0380 · Gemcitabine · Irinotecan — 82 sites
- TRIALPHASE1RECRUITING
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
PF-08046050 · bevacizumab · 5-Fluorouracil (5-FU) — 48 sites
- TRIALPHASE2RECRUITING
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Pemigatinib · Computed Tomography (CT) · Magnetic Resonance Imaging — 109 sites
- TRIALPHASE1 / PHASE2RECRUITING
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
RMC-6236 · mFOLFOX6 regimen · bevacizumab — 32 sites
- TRIALPHASE3RECRUITING
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Setidegrasib · Oxaliplatin · Leucovorin — 79 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
FMC-376 — 26 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.